Paper Details
- Home
- Paper Details
Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo.
Author: BurgG, DummerR, GoldingerS M, LäuchliS, SchmidP, SeifertB
Original Abstract of the Article :
A large variety of therapeutic agents are being used for the treatment of vitiligo, but treatment remains a challenge. Recently, monochromatic phototherapies such as 311-nm narrowband ultraviolet B therapy and 308-nm xenon chloride excimer laser have been reported to be an effective and safe therape...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1111/j.1468-3083.2006.02016.x
データ提供:米国国立医学図書館(NLM)
Treating Vitiligo: Finding the Oasis of Repigmentation
Vitiligo, a skin condition characterized by loss of pigmentation, can be a frustrating desert of depigmentation. This research explores the combination of 308-nm xenon chloride excimer laser and topical calcipotriol as a potential oasis of repigmentation.
Phototherapy and Topical Treatment: A Synergistic Approach
The study suggests that combining phototherapy with topical calcipotriol may enhance repigmentation, akin to a desert traveler utilizing both a compass and a map to find their way.
Dr. Camel's Conclusion
Vitiligo can be a challenging condition, but this research offers hope for improved treatment options. Finding the right combination of therapies, like discovering a hidden oasis of repigmentation in the desert, can lead to more effective outcomes.
Date :
- Date Completed 2007-07-18
- Date Revised 2014-11-20
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.